Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
fda
4
×
food and drug administration
4
×
life sciences
4
×
national blog main
raleigh-durham blog main
san francisco blog main
san francisco top stories
4
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
national top stories
new york blog main
new york top stories
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
clinical trials
deals
startups
alder biopharmaceuticals
alex azar
alirocumab
american patients first
american society of clinical oncology (asco)
amgen
anti-inflammatory drugs
arcturus therapeutics
What
drug
4
×
afternoon
ahead
ambien
american
amgen
annual
anticipated
approval
asco
attendees
attention
awaited
biotech
blueprint
building
camp’s
cancer
candidates
cash
chicago
city
class
clinical
combinations
community’s
cost
cut
days
deal
details
developed
developer
disease
drugs
established
expanding
fda
firm
focus
Language
Current search:
drug
×
biotech
×
" life sciences "
×
" san francisco top stories "
×
fda
×
" food and drug administration "
×
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines
@xconomy.com
6 years ago
Trump Pledges Lower Drug Prices, But Blueprint Is Short on Details
@xconomy.com
6 years ago
United Therapeutics Reaches $141M Deal for PAH Drug Firm SteadyMed
